Sign up to save your podcasts
Or
Share Dealmaking in Life Sciences: Private Equity Insights & Due Diligence
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dealmaking in Life Sciences: Private Equity Insights & Due Diligence
In this episode of EisnerAmper's Private Equity Dealbook, Elana Margulies-Snyderman, Director, Publications, speaks with Robert Esposito, Managing Director in the firm's Transaction Advisory Services Group. Bob shares his outlook for dealmaking in the life sciences industry, including the opportunities, challenges and due diligence considerations. He also discusses what private equity managers look for in the buy-side process to better ensure that both a mutually beneficial and efficient transaction can be consummated in today's economic and transaction market environment.
The conversation dives deep into life sciences M&A, private equity dealmaking, and healthcare investment strategies. Whether you’re an investor, entrepreneur, or advisor, you’ll gain insights into how deals are structured, what risks matter most, and where the biggest opportunities lie in 2025.
View all episodes
By Eisner Advisory Group LLC
4.7
1010 ratings
In this episode of EisnerAmper's Private Equity Dealbook, Elana Margulies-Snyderman, Director, Publications, speaks with Robert Esposito, Managing Director in the firm's Transaction Advisory Services Group. Bob shares his outlook for dealmaking in the life sciences industry, including the opportunities, challenges and due diligence considerations. He also discusses what private equity managers look for in the buy-side process to better ensure that both a mutually beneficial and efficient transaction can be consummated in today's economic and transaction market environment.
The conversation dives deep into life sciences M&A, private equity dealmaking, and healthcare investment strategies. Whether you’re an investor, entrepreneur, or advisor, you’ll gain insights into how deals are structured, what risks matter most, and where the biggest opportunities lie in 2025.